Immunome Stock Gets Weaker EPS Forecast from HC Wainwright

Immunome, Inc. (NASDAQ:IMNM) – Analysts at HC Wainwright lowered their FY2026 earnings estimates for shares of Immunome in a report released on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($2.64) for the year, down from their prior forecast of ($2.45). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for Immunome’s Q4 2026 earnings at ($0.76) EPS, FY2027 earnings at ($2.71) EPS, FY2028 earnings at ($2.41) EPS, FY2029 earnings at ($1.63) EPS and FY2030 earnings at ($0.42) EPS.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.14).

Other equities research analysts have also issued reports about the stock. Piper Sandler lowered their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Tuesday. William Blair assumed coverage on shares of Immunome in a report on Friday, October 16th. They issued an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Thursday, October 15th. Wall Street Zen downgraded shares of Immunome from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th. Finally, Truist Financial increased their price target on Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Fourteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Immunome presently has an average rating of “Moderate Buy” and an average price target of $33.85.

Immunome Stock Performance

Shares of NASDAQ:IMNM opened at $19.07 on Thursday. The company has a market cap of $2.17 billion, a P/E ratio of -7.22 and a beta of 2.68. Immunome has a one year low of $16.11 and a one year high of $30.06. The business’s 50-day simple moving average is $20.99 and its 200 day simple moving average is $22.30.

Institutional Trading of Immunome

Several institutional investors and hedge funds have recently bought and sold shares of IMNM. BlackRock Inc. purchased a new stake in Immunome during the second quarter valued at about $186,588,000. Primecap Management Co. CA acquired a new position in shares of Immunome in the second quarter worth about $97,081,000. Bank of America Corp DE purchased a new position in shares of Immunome in the second quarter worth approximately $13,729,000. Parkman Healthcare Partners LLC purchased a new position in shares of Immunome in the second quarter worth approximately $12,591,000. Finally, Wellington Management Group LLP raised its holdings in shares of Immunome by 10.1% during the second quarter. Wellington Management Group LLP now owns 5,210,216 shares of the company’s stock valued at $110,404,000 after acquiring an additional 478,239 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Insider Buying and Selling at Immunome

In other news, insider Jack Higgins sold 13,200 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $25.32, for a total transaction of $334,224.00. Following the completion of the sale, the insider directly owned 65,050 shares of the company’s stock, valued at $1,647,066. This trade represents a 16.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.21% of the stock is currently owned by corporate insiders.

Recent Immunome Headlines

These are some of the IMNM headlines that stood out recently:

• Neutral Sentiment: Price targets were trimmed but remain above the $19.07 reference price: Piper Sandler cut its target from $33 to $30 and kept an Overweight rating; Stifel Nicolaus lowered its target from $24 to $23 and maintained Hold. The cuts are cautious, while the ratings and targets indicate potential upside. Piper Sandler target article Stifel Nicolaus article
• Negative Sentiment: HC Wainwright reduced its Q4 2026 EPS forecast to a loss of $0.76 per share from a loss of $0.68, and cut its FY2026 estimate to a loss of $2.64 from $2.45. It also lowered estimates for FY2027–FY2030, including changing its FY2029 forecast from $0.40 profit to a $1.63 loss and its FY2030 forecast from $1.08 profit to a $0.42 loss. These revisions point to a longer path to profitability and could weigh on investor sentiment.

Immunome Company Profile

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.